Use of sophocarpine in preparing medicine for treating diseases induced by coxsackie B virus

A technology of sophocarpine and drugs, which is applied in the field of pharmacy, can solve problems such as poor drug treatment effects, achieve the effects of rich drug sources, simple preparation, and improved cure rate

Inactive Publication Date: 2009-04-29
RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] The purpose of the present invention is to provide a kind of application of sophocarpine in the preparation of the medicine for the treatment of Coxsackie B virus-induced diseases, and described sophocarpine or its pharmaceutically acceptable salt will solve the problem of treating Coxsackie B virus in the prior art. Viral dilated cardiomyopathy, viral hypertrophic cardiomyopathy, viral coronary arteritis, viral pericarditis, viral endocarditis, viral valvulitis, pneumonia, bronchitis, hepatitis, cerebral palsy caused by B virus Technical problems of ineffective drug therapy for inflammation, meningitis, pancreatitis, diabetes mellitus, epidemic myalgia, epidemic chest pain

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of sophocarpine in preparing medicine for treating diseases induced by coxsackie B virus
  • Use of sophocarpine in preparing medicine for treating diseases induced by coxsackie B virus
  • Use of sophocarpine in preparing medicine for treating diseases induced by coxsackie B virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0075] Example 1 In vitro test

[0076] The cytopathic inhibition method was used to determine the toxicity and antiviral (CVB3m) effect of sophocarpine on vero cells. The results of comparison of sophocarpine and "positive drugs" (morpholinguanidine, ribavirin) on vero cells proved Sophocarpine is low toxic and has obvious resistance to CVB 3 m's drug

[0077] 1. Preparation method of three mother liquors of sophocarpine, morpholinoguanidine and ribavirin

[0078] Sophocarpine is 100mg / ml and the drug concentration (10000μg / ml) is diluted to 1% in RPMI-1640 culture medium without calf serum as mother liquor, and it is stored aseptically at low temperature. The preparation method of morpholinoguanidine and ribavirin is the same as above.

[0079] (1) Determination of the toxicity of three drugs on vero cells

[0080] The concentration of 1% sophocarpine injection was diluted with calf serum-free RPMI-1640 culture solution to different concentrations (from 1:2 serial dilution to 1:...

Embodiment 2

[0120] Example 2 In vivo test

[0121] (1) The anti-virus studies of sophocarpine injection in modeling mice showed that it has low toxicity and obvious anti-CBV effect, and the mice in the drug treatment group can survive for more than 50 days. However, 100% of the untreated control group died within 8 days, indicating that sophocarpine can reduce the mortality of infected mice and prolong the survival period. In the virus group, various organ cells were significantly necrotic and inflammatory cell infiltration. However, the heart, lung, liver, pancreas, brain, and skeletal muscle of the treatment group had no obvious pathological changes, so sophocarpine was against CVB 3 The role of m, which has a significant therapeutic effect on the diseases of various organs caused by Coxsackie B.

[0122] (2) Using cell pathogenic effect (CPE)

[0123] The cytopathic method (micromethod) was used to determine the anti-CVB3m effect of sophocarpine on Vero cells in the serum of CVB3m-infected...

Embodiment 3

[0127] Example 3 Epidemic myalgia and chest pain

[0128] Epidemic chest pain: All five types of Coxsackie B virus can cause muscle pain and muscle weakness. The incubation period is 2 to 5 days and can be extended to 2 weeks. Mainly manifested as fever and paroxysmal myalgia, myalgia can involve the whole body skeletal muscle. The chest and abdomen are more common, especially the diaphragm is the most susceptible, often concurrent with aseptic meningitis. Chest pain varies from severity to severity, even causing shock. Chest pain is worse when the chest muscles are active. Chest X-ray examination revealed no abnormalities. Current treatment is with analgesics or morphine and codeine. It can be relieved a few days after analgesic treatment. But there may be repeated attacks in the future, the main pathological changes are inflammation and necrosis of skeletal muscle cells. If the patient's blood WBC is detected with CVB-RNA by PCR in time, the diagnosis can be confirmed. Effective...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses the application of sophocarpine and medical salts thereof in medicines treating viral dilated cardiomyopath, viral hypertrophic cardiomyopathy, viral coronaritis, viral pericarditis, viral endocarditis, viral valvulitism, pneumonia, bronchitis, hepatitis, encephalitis, meningitis, pancreatitis, epidemic myalgia and epidemic pleurodynia which are caused by Coxsackie B virus. The sophocarpine and the medical salts thereof which are taken as medicines for treating all related internal organ diseases caused by Coxsackie B virus can increase the cure rate, reduce the death rate and cause no obvious cytotoxic effect. Meanwhile, the sophocarpine is applicable to the industrialized production due to the rich medical herb resources, simple and convenient preparation and low cost.

Description

Technical field [0001] The invention belongs to the field of pharmacy, and relates to a medical preparation, in particular to the application of sophocarpine, in particular to the application of sophocarpine in the preparation of drugs for treating Coxsackie B virus-induced diseases. Background technique [0002] Sophocarpine (sophocarpine) is an effective monomer extracted from the dried roots and ground parts of Sophora flavescens of the leguminous Sophorae plant and Sophora flavescens of the leguminous Sophora plant Sophocarpine. 15 H 22 ON 2 , The melting point is 53-54℃, and its structural formula is (I): [0003] [0004] Sophocarpine against coxsackie virus B (coxsackie virus B) and its pharmaceutical preparation have been disclosed in an authorized patent 99119850.6 of the applicant. In addition, the inventor of the present application has also discovered the therapeutic effect of sophocarpine against the disease caused by the coronavirus (SARS Virus), and the relevant ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4375A61K9/08A61K9/10A61K9/14A61K9/20A61K9/48A61P31/14A61P1/08A61P9/10A61P11/00A61P29/00
Inventor 陈曙霞
Owner RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap